Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Minassian, Angela M ^a   Ronan, Edward O ^a   Poyntz, Hazel ^a   Hill, Adrian V S ^a   McShane, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BCG VACCINE; GAMMA INTERFERON; UNCLASSIFIED DRUG; VACCINIA VIRUS VECTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM CULTURE; BCG VACCINATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROVOCATION TEST; QUANTITATIVE STUDY; SINGLE DRUG DOSE; TUBERCULIN TEST; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; BCG VACCINE; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; TUBERCULOSIS VACCINES;

EID: 79956353792     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019840     Document Type: Article

References (41)

1. Reece WH, Pinder M, Gothard PK, Milligan P, Bojang K, et al. (2004) A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 10: 406-410.
2. Moorthy VS, Diggs C, Ferro S, Good MF, Herrera S, et al. (2009) Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine 27: 5719-5725.
3. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, et al. (2008) Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 167: 775-785.
4. Marwick C, (1998) Volunteers in typhoid infection study will aid future vaccine development. JAMA 279: 1423-1424.
5. Minassian AM, McShane H, (2008) Tuberculosis vaccines: present and future. Expert Rev Respir Med 2: 721-738.
6. Collins FM, (1971) Immunogenicity of various mycobacteria and the corresponding levels of cross-protection developed between species. Infect Immun 4: 688-696.
7. Chen L, Wang J, Zganiacz A, Xing Z, (2004) Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect Immun 72: 238-246.
8. Lagranderie MR, Balazuc AM, Deriaud E, Leclerc CD, Gheorghiu M, (1996) Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect Immun 64: 1-9.
9. Dobakhti F, Naghibi T, Taghikhani M, Ajdary S, Rafinejad A, et al. (2009) Adjuvanticity effect of sodium alginate on subcutaneously injected BCG in BALB/c mice. Microbes Infect 11: 296-301.
10. Garnier T, Eiglmeier K, Camus JC, Medina N, Mansoor H, et al. (2003) The complete genome sequence of Mycobacterium bovis. Proc Natl Acad Sci U S A 100: 7877-7882.
11. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Jama 271: 698-702.
12. Lockhart E, Green AM, Flynn JL, (2006) IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 177: 4662-4669.
13. Umemura M, Yahagi A, Hamada S, Begum MD, Watanabe H, et al. (2007) IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J Immunol 178: 3786-3796.
14. Hanekom WA, (2005) The immune response to BCG vaccination of newborns. Ann N Y Acad Sci 1062: 69-78.
15. Abadie V, Badell E, Douillard P, Ensergueix D, Leenen PJ, et al. (2005) Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 106: 1843-1850.
16. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, et al. (1998) Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4: 397-402.
17. Sridhar S, Reyes-Sandoval A, Draper SJ, Moore AC, Gilbert SC, et al. (2008) Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J Virol 82: 3822-3833.
18. Kong Y, Yao H, Ren H, Subbian S, Cirillo SL, et al. (2010) Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice. Proc Natl Acad Sci U S A 107: 12239-12244.
19. Santosuosso M, McCormick S, Zhang X, Zganiacz A, Xing Z, (2006) Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun 74: 4634-4643.
20. Wang J, Santosuosso M, Ngai P, Zganiacz A, Xing Z, (2004) Activation of CD8 T cells by mycobacterial vaccination protects against pulmonary tuberculosis in the absence of CD4 T cells. J Immunol 173: 4590-4597.
21. Jeon BY, Derrick SC, Lim J, Kolibab K, Dheenadhayalan V, et al. (2008) Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infect Immun 76: 5173-5180.
22. Olsen AW, Brandt L, Agger EM, van Pinxteren LA, Andersen P, (2004) The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis. Scand J Immunol 60: 273-277.
23. Ladel CH, Daugelat S, Kaufmann SH, (1995) Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol 25: 377-384.
24. Caruso AM, Serbina N, Klein E, Triebold K, Bloom BR, et al. (1999) Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. J Immunol 162: 5407-5416.
25. Saunders BM, Frank AA, Orme IM, Cooper AM, (2002) CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol 216: 65-72.
26. Scanga CA, Mohan VP, Yu K, Joseph H, Tanaka K, et al. (2000) Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. J Exp Med 192: 347-358.
27. Cowley SC, Elkins KL, (2003) CD4+ T cells mediate IFN-gamma-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J Immunol 171: 4689-4699.
28. Feng CG, Britton WJ, (2000) CD4+ and CD8+ T cells mediate adoptive immunity to aerosol infection of Mycobacterium bovis bacillus Calmette-Guerin. J Infect Dis 181: 1846-1849.
29. Wangoo A, Sparer T, Brown IN, Snewin VA, Janssen R, et al. (2001) Contribution of Th1 and Th2 cells to protection and pathology in experimental models of granulomatous lung disease. J Immunol 166: 3432-3439.
30. Andersen P, Smedegaard B, (2000) CD4(+) T-cell subsets that mediate immunological memory to Mycobacterium tuberculosis infection in mice. Infect Immun 68: 621-629.
31. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S, (2006) Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity. Vaccine 24: 443-451.
32. Gruppo V, Orme IM, (2002) Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with Mycobacterium tuberculosis. Tuberculosis (Edinb) 82: 267-273.
33. Izumi T, Costello R, (1971) Temporal development of resistance to pulmonary tuberculosis in Swiss albino mice. J Exp Med 133: 376-388.
34. Lefford MJ, (1980) Macrophage activation and resistance to pulmonary tuberculosis. Infect Immun 28: 508-515.
35. Tchilian EZ, Desel C, Forbes EK, Bandermann S, Sander CR, et al. (2009) Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect Immun 77: 622-631.
36. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, et al. (2008) Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 181: 4955-4964.
37. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, et al. (2004) Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173: 6357-6365.
38. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV, (2002) Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun 70: 1623-1626.
39. Magdalena J, Supply P, Locht C, (1998) Specific differentiation between Mycobacterium bovis BCG and virulent strains of the Mycobacterium tuberculosis complex. J Clin Microbiol 36: 2471-2476.
40. Talbot EA, Williams DL, Frothingham R, (1997) PCR identification of Mycobacterium bovis BCG. J Clin Microbiol 35: 566-569.
41. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, et al. (2003) Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171: 1602-1609.